Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.
about
Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular DeliveryAdvanced drug delivery and targeting technologies for the ocular diseasesManagement of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentInjectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo StudyA new model for in vitro testing of vitreous substitute candidates.Synthesis and biocompatibility of a biodegradable and functionalizable thermo-sensitive hydrogelSlow-release drug delivery through Elvax 40W to the rat retina: implications for the treatment of chronic conditions.Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Drug delivery to the eye: what benefits do nanocarriers offer?Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels.Weak Bond-Based Injectable and Stimuli Responsive Hydrogels for Biomedical Applications.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.Injectable hydrogels for ophthalmic applications.Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.
P2860
Q26740005-EB9E1BA5-DABE-4F51-87C2-A508A7D7A142Q26747220-18E98074-A3C5-4457-88B8-A4EF9D5078BCQ26824335-A845ABA6-A3D4-45EA-85F0-7EF5C68D04D3Q35166714-B44DC1E2-27EB-4D49-8F4A-BEC8C907D741Q35212688-9CE11F6F-B350-4120-BF01-1533D732AACFQ36345116-7492D83C-068F-4F54-8DAB-8ED1C0F42281Q36788228-83D18B5F-3073-41FC-87D4-40A228791D77Q38934604-232AF4F0-AC95-4E6A-8E04-6D134EC8C5BAQ39066090-BD35C0C6-DC41-4DC5-BCE9-B637966B5896Q39130097-0035189E-5A06-4057-A55A-76978949FD42Q47330134-8B1D6EB2-BA68-4CD7-8E09-68D32D92B446Q47418109-2CDB0897-E4D4-4909-A6A1-51AB4D8996E5Q47729137-54A4F959-2ECF-425C-87A6-EE196EB3BB59Q48902538-E91C1AE3-8589-42DD-9EF5-0E16DBD3D900Q50072638-B25345BC-77D2-4E7A-93C4-9AC0737C1BD9Q53577573-388EAC7E-7BAB-43C7-80D4-6E082AD1C527
P2860
Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@en
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@nl
type
label
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@en
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@nl
prefLabel
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@en
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@nl
P2093
P2860
P356
P1476
Biocompatible reverse thermal ...... ravitreal bevacizumab in vivo.
@en
P2093
Britta M Rauck
Carlos A Medina Mendez
Daewon Park
Richard A Bilonick
Thomas R Friberg
Veeral Shah
P2860
P304
P356
10.1167/IOVS.13-13120
P407
P50
P577
2014-01-23T00:00:00Z